To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to conduct a study to assess the potential for expanding the safe and effective use of reprocessed single-use devices, and for other purposes.
The source supplies the latest action, but no lifecycle stage.
Latest action (13 Aug 2026): Referred to the House Committee on Energy and Commerce.
What this bill does
H.R. 10088 would direct the Secretary of Health and Human Services, through the Food and Drug Administration (FDA), to conduct a study on expanding the safe and effective use of reprocessed single-use medical devices. The study would prioritize patient safety and infection prevention, examining devices based on risk and clinical use. It would also focus on opportunities and challenges for third-party reprocessors.
The study's scope includes evaluating current FDA pathways for reprocessing, comparing third-party versus in-house reprocessing, assessing operational feasibility like sterilization capacity and staffing, and analyzing financial and environmental impacts, including waste reduction and cost savings. It would also consider liability and accountability. The Secretary must consult with various non-Federal and Federal entities.
This bill was introduced in the House of Representatives on August 13, 2026, and referred to the Committee on Energy and Commerce. It has not yet advanced beyond the introduction stage. If enacted, the Secretary would have one year from the enactment date to submit a report to Congress detailing the study's findings and recommendations.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Timeline
13 Aug 2026
Referred to the House Committee on Energy and Commerce.
Common questions
- What does H.R. 10088 do?
- H.R. 10088 would direct the Secretary of Health and Human Services, through the Food and Drug Administration (FDA), to conduct a study on expanding the safe and effective use of reprocessed single-use medical devices. The study would prioritize patient safety and infection prevention, examining devices based on risk and clinical use. It would also focus on opportunities and challenges for third-party reprocessors. The study's scope includes evaluating current FDA pathways for reprocessing, comparing third-party versus in-house reprocessing, assessing operational feasibility like sterilization capacity and staffing, and analyzing financial and environmental impacts, including waste reduction and cost savings. It would also consider liability and accountability. The Secretary must consult with various non-Federal and Federal entities. This bill was introduced in the House of Representatives on August 13, 2026, and referred to the Committee on Energy and Commerce. It has not yet advanced beyond the introduction stage. If enacted, the Secretary would have one year from the enactment date to submit a report to Congress detailing the study's findings and recommendations.
- Has H.R. 10088 become law?
- The source does not supply a confirmed lifecycle stage for H.R. 10088. Check the latest action and official source below.
- Who sponsored H.R. 10088?
- H.R. 10088 was sponsored by Rep. Foushee, Valerie P. [D-NC-4] (D-NC), with 0 cosponsors.
- What's the latest action on H.R. 10088?
- Referred to the House Committee on Energy and Commerce. (13 Aug 2026).
Related bills in Health
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Choices for Increased Mobility Act of 2026
Access to Medical Supplies Act
Lower Premiums, Faster Payments Act
More bills from Rep. Foushee, Valerie P. [D-NC-4]
To amend the Internal Revenue Code of 1986 to establish a credit to incentivize the use of certain low-emission anesthetic gases by health care facilities, and for other purposes.
American Tariff Rebate Act
Seizure Safe Schools Act of 2026
Stop Prison Price Gouging Act of 2026
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.